Abeona Therapeutics Inc. (NASDAQ:ABEO) has been given a $15.00 target price by stock analysts at FBR & Co in a research note issued to investors on Wednesday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. FBR & Co’s price objective would indicate a potential upside of 159.52% from the company’s current price.

Several other research analysts also recently weighed in on the company. Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Friday, August 5th. Maxim Group reiterated a “buy” rating and issued a $6.00 price target on shares of Abeona Therapeutics in a report on Tuesday, August 2nd. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Finally, Cantor Fitzgerald initiated coverage on Abeona Therapeutics in a report on Wednesday, September 7th. They issued a “buy” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Abeona Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.40.

Abeona Therapeutics (NASDAQ:ABEO) traded up 13.49% during mid-day trading on Wednesday, reaching $6.56. The company’s stock had a trading volume of 1,128,295 shares. The stock’s market capitalization is $220.06 million. The stock’s 50 day moving average price is $4.28 and its 200 day moving average price is $3.09. Abeona Therapeutics has a 1-year low of $2.05 and a 1-year high of $6.74.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fbr-co-analysts-give-abeona-therapeutics-inc-abeo-a-15-00-price-target.html

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Analysts expect that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Royce & Associates LP boosted its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC boosted its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the period. 19.95% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.